Trump's Executive Order to Slash Prescription Drug Prices by 30-80%: A Global Economic Conundrum

The United States plans to sign an executive order to significantly reduce prescription drug prices through a 'Most Favoured Nation' policy, aiming to slash prices by 30 to 80 percent. This move has both local and global implications, with experts warning that it could lead to unintended consequences for lower-income countries like Nigeria. Meanwhile, Nigeria is taking steps to strengthen its local pharmaceutical manufacturing, with the goal of increasing domestic production to 70 percent by 2030.

Key Takeaways:

• The executive order aims to reduce prescription drug prices in the United States by 30 to 80 percent through a 'Most Favoured Nation' policy, making the US pay the same price for medications as the country with the lowest price globally.
• Mojisola Adeyeye, Director General of Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), emphasized the need for urgent local solutions to address Nigeria's reliance on imported medications, with more than 70 percent of pharmaceutical products being imported.
• Nigeria's Pharmaceutical Society reports that domestic production currently meets only 25 percent of national demand, while the country's healthcare expenditure is $10 billion annually, with 62 percent of spending coming from out-of-pocket payments.
• The recent ban on the importation of pharmaceutical products already available locally by Bola Tinubu has been welcomed as a bold step toward industrial self-reliance, and Adeyeye praised the policy as aligning with the urgent need to protect and grow Nigeria's pharmaceutical sector.
• The Coordinating Minister of Health and Social Welfare, Muhammad Pate, recently unveiled the Presidential Initiative for Unlocking the Healthcare Value Chain, aiming to increase local pharmaceutical manufacturing to 70 percent by 2030.
• Analysts agree that scaling up local drug production in Nigeria is critical to securing the country's healthcare future, and that such reforms would have benefits beyond healthcare, including job creation, enhanced self-sufficiency, and reduced national healthcare costs.

Statistics:

• The US plans to reduce prescription drug prices by 30 to 80 percent through a 'Most Favoured Nation' policy.
• Nigeria imports more than 70 percent of its pharmaceutical products, accounting for a major share of its $10 billion annual healthcare expenditure.
• Out-of-pocket payments make up 62 percent of healthcare spending in Nigeria, reflecting limited insurance coverage and economic disparities.
• Domestic production meets only 25 percent of national demand, according to the Pharmaceutical Society of Nigeria.
• Nigeria aims to increase local pharmaceutical manufacturing to 70 percent by 2030, according to the Presidential Initiative for Unlocking the Healthcare Value Chain.

Sources:

• [Source 1] Trump, D. (2023). Truth Social post.
• [Source 2] Adeyeye, M. (2023). 38th Victor Olufemi Marquis Memorial Lecture at Obafemi Awolowo University (OAU), Ile-Ife, Osun State, Nigeria.
• [Source 3] Pharmaceutical Society of Nigeria. (n.d.). National Pharmaceutical Production and Demand Report.
• [Source 4] Muhammad Pate. (2023). Presidential Initiative for Unlocking the Healthcare Value Chain.